Search Results 51-60 of 16462 for Emicizumab
Everolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as bevacizumab, can interfere ...
Emicizumab-kxwh (subcutaneous route). Emla. Also known as. Lidocaine and prilocaine (topical application route). Emo-Cort. Also known as. Hydrocortisone ...
This trial also studies the outcomes of patients with mixed phenotype acute leukemia (MPAL), and B-lymphoblastic lymphoma (B-LLy) when treated with ALL therapy ...
This phase III trial studies whether inotuzumab ozogamicin added to post-induction chemotherapy for patients with High-Risk B-cell Acute Lymphoblastic Leukemia ...
Hematology — Learn about innovative diagnosis and treatment options for blood diseases, including cancers, at Mayo Clinic.
99mTc-MIP-1404 is a radioactive diagnostic imaging agent indicated for imaging men with newly diagnosed prostate cancer whose biopsy indicates a ...
Inclusion Criteria: Understands the study procedures and can give signed informed consent (as specified in Section 10.1.3), which includes compliance with ...
This partially randomized phase III trial studies the side effects of inotuzumab ozogamicin and how well it works when given with frontline chemotherapy in ...
Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and ...
ABBV-383 is an investigational drug being developed for the treatment of R/R Multiple Myeloma (MM). This study includes 2 parts; step-up dose optimization (Part ...
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
Hurry to 3X your gift’s impact on cancer research and care!